Skip to main content

Table 1 Baseline description and parameters of GBM datasets

From: DNA methylation-based age acceleration observed in IDH wild-type glioblastoma is associated with better outcome—including in elderly patients

Datasets DKFZ (%) EORTC/NCIC & LN-Pilot (%) Nordic (%) TCGA (%) P-Value
N 214 (100) 177 (100) 105 (100) 99 (100)  
Sex      0.1994
Female 101 (47) 66 (37) 40 (38) 42 (42)  
Male 113 (53) 111 (63) 65 (62) 57 (58)  
Patient age [years]       < 0.0001
Min 29 27 60 33  
Max 86 70 83 85  
Mean, SD 60.34 ± 11.25 54.35 ± 8.98 70.82 ± 4.66 61.95 ± 10.64  
DNAm age [years]      0.0001
Min 40.02 39.56 57.90 30.11  
Max 174.01 167.42 180.10 186.71  
Mean, SD 94.65 ± 22.58 94.13 ± 26.13 107.75 ± 25.17 98.71 ± 27.72  
Age Acc [years]      0.1737
Min − 13.45 − 9.50 − 7.19 − 14.89  
Max 135.01 104.14 108.49 120.71  
Mean (SD) 34.31 ± 21.25 39.78 ± 24.71 36.93 ± 25.09 36.76 ± 26.67  
GBM subgroup      0.0141
GBM_MES 48 (22) 66 (37) 43 (41) 31 (31)  
GBM_RTK_I 51 (24) 30 (17) 20 (19) 19 (19)  
GBM_RTK_II 115 (54) 81 (46) 42 (40) 49 (49)  
MGMT-STP27      0.4871
U 100 (47) 91 (51) 55 (52) 55 (56)  
M 114 (53) 86 (49) 50 (48) 44 (44)  
MGMT score      0.3412
Min − 5.58 − 10.48 − 4.09 − 11.68  
Max 6.98 7.35 8.16 6.34  
Mean, SD 0.62 ± 3.59 0.22 ± 3.38 0.32 ± 3.31 − 0.23 ± 3.85  
HM purity      0.6177
Min 0.31 0.42 0.42 0.39  
Max 0.99 0.95 0.98 0.98  
Mean, SD 0.73 ± 0.14 0.74 ± 0.14 0.75 ± 0.14 0.75 ± 0.14  
Global HM entropy      0.9938
Min 0.45 0.47 0.47 0.49  
Max 0.64 0.64 0.62 0.63  
Mean, SD 0.55 ± 0.03 0.55 ± 0.03 0.55 ± 0.03 0.55 ± 0.03  
HME Prom CpG:      0.2526
Min 0.27 0.29 0.29 0.28  
Max 0.48 0.47 0.45 0.41  
Mean, SD 0.36 ± 0.03 0.36 ± 0.03 0.36 ± 0.03 0.36 ± 0.03  
  1. Description of datasets used in the analyses that were restricted to IDHwt GBM WHO grade 4, 2021, and corresponding parameters determined in this study. Significant differences between the datasets were observed for patient age and DNA methylation age of GBM (DNAm age), and GBM subtypes.
  2. Age Acc, DNAm age acceleration; GBM subgroup, methylation-based classification into mesenchymal (MES), RTK I and RTK II; Global HM entropy, human methylation based entropy of all genomic regions; HME Prom CpG, human methylation based entropy in promoter CpG islands; HM purity, human methylation based determination of sample purity; MGMT promoter methylation status, unmethylated U, methylated M, classified by MGMT-STP27 procedure; MGMT score, calculated with MGMT-STP27; SD, standard deviation.